Page 95 - Read Online

Page 12 of 12 Loria et al. Hepatoma Res 2018;4:59 I http://dx.doi.org/10.20517/2394-5079.2018.75

76. Seitz K, Strobel D, Bernatik T, Blank W, Friedrich-Rust M, Herbay Av, Dietrich CF, Strunk H, Kratzer W, Schuler A. Contrast-enhanced
ultrasound (CEUS) for the characterization of focal liver lesions-prospective comparison in clinical practice: CEUS vs. CT (DEGUM
multicenter trial). Parts of this manuscript were presented at the Ultrasound Dreiländertreffen. Ultraschall Med 2009;30:383-9.
77. Seitz K, Bernatik T, Strobel D, Blank W, Friedrich-Rust M, Strunk H, Greis C, Kratzer W, Schuler A. Contrast-enhanced ultrasound (CEUS)
for the characterization of focal liver lesions in clinical practice (DEGUM multicenter trial): CEUS vs MRI--a prospective comparison in
269 patients. Ultraschall Med 2010;31:492-9.
78. Goto E, Masuzaki R, Tateishi R, Kondo Y, Imamura J, Goto T, Ikeda H, Akahane M, Shiina S, Omata M, Yoshida H, Koike K. Value of
post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma. J
Gastroenterol 2012;47:477-85.
79. Xu HX, Lu MD, Liu GJ, Xie XY, Xu ZF, Zheng YL, Liang JY. Imaging of peripheral cholangiocarcinoma with low-mechanical index
contrast-enhanced sonography and SonoVue: initial experience. J Ultrasound Med 2006;25:23-33.
80. Guo L-H, Xu H-X. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma:
controversy over the ASSLD Guideline. Biomed Res Int 2015;2015:1-5.
81. Li R, Yuan MX, Ma KS, Li XW, Tang CL, Zhang XH, Guo DY, Yan XC. Detailed analysis of temporal features on contrast enhanced
ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis. PLoS One 2014; 9:e98612.
82. Zhang J, Yu Y, Li Y, Wei L. Diagnostic value of contrast-enhanced ultrasound in hepatocellular carcinoma: a meta-analysis with evidence
from 1998 to 2016. Oncotarget 2017;8:75418-26.
83. Masuzaki R, Shiina S, Tateishi R, Yoshida H, Goto E, Sugioka Y, Kondo Y, Goto T, Ikeda H, Omata M, Koike K. Utility of contrast-
enhanced ultrasonography with Sonazoid in radiofrequency ablation for hepatocellular carcinoma. J Gastroenterol Hepatol 2011; 26:759-64.
84. Chan AK, Hegarty C, Klass D, Yoshida E, Chung S, Liu DM, Ho SG, Harris AC. The role of contrast-enhanced ultrasound in guiding radio
frequency ablation of hepatocellular carcinoma: a retrospective study. Can Assoc Radiol J 2015;66:171-8.
85. Chiorean L, Tana C, Braden B, Caraiani C, Sparchez Z, Cui XW, Baum U, Dietrich CF. Advantages and limitations of focal liver lesion
assessment with ultrasound contrast agents: comments on the European Federation of Societies for Ultrasound in Medicine and Biology
(EFSUMB) Guidelines. Med Princ Pract 2016;25:399-407.
86. Loria F, Loria G, Basile S, Crea G, Frosina L, Frosina F. Role of contrast-enhanced ultrasound in the evaluation of vascularization of
hepatocellular carcinoma. Hepatoma Research 2016;2:316-22.
87. Piscaglia F, Bolondi L; Italian Society for Ultrasound in Medicine and Biology (SIUMB) Study Group on Ultrasound Contrast Agents. The
safety of SonoVue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol 2006;32:1369-75.